Evidence map›Paper›PMID 34805376›Full record

ReviewGlobal cardiology science & practice2021

Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre.

Ioanna Istampoulouoglou, Georgios Dimitriou, Selina Späni, Andreas Christ, Barbara Zimmermanns, Sarah Koechlin, Oliver Stoeckmann, Clemens Winterhalder, David Marono, Valeriu Toma and 1 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Global cardiology science & practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Myocarditis, pericarditis, and COVID-19 mRNA-vaccination.Global cardiology science & practice · 2022
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Ioanna IstampoulouoglouDepartment of Clinical Pharmacology & Toxicology, University Hospital and University of Basel, Switzerland.
Georgios DimitriouEmergency department, Cantonal Hospital Aarau, Switzerland.
Selina SpäniHospital Pharmacy, Cantonal Hospital Basel Landschaft, Liestal, Switzerland.
Andreas ChristIntensive Care Unit, Cantonal Hospital Basel Landschaft, Liestal, Switzerland.
Barbara ZimmermannsDepartment of Clinical Pharmacology & Toxicology, University Hospital and University of Basel, Switzerland.
Sarah KoechlinDepartment of Clinical Pharmacology & Toxicology, University Hospital and University of Basel, Switzerland.
Oliver StoeckmannDepartment of Clinical Pharmacology & Toxicology, University Hospital and University of Basel, Switzerland.
Clemens WinterhalderDepartment of Internal Medicine, University Hospital Basel, Basel, Switzerland.
David MaronoMedical Outpatient Department, University Hospital Basel, Basel, Switzerland.
Valeriu TomaSwissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland.
Anne B Leuppi-TaegtmeyerDepartment of Clinical Pharmacology & Toxicology, University Hospital and University of Basel, Switzerland.
University Hospital of Basel · CHUniversity of Basel · CHTheological Seminary Bienenberg · CHKantonsspital Aarau · CHSwissmedic · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this article we summarize suspected adverse events following immunization (AEFI) of pericarditis, myocarditis and perimyocarditis that were reported by our regional pharmacovigilance centre after COVID-19 mRNA-vaccination and discuss their association with these vaccines. Seventeen cases were reported between March and July 2021. Of these, nine had perimyocarditis, five myocarditis and three pericarditis. Twelve patients were male (71%). The median age was 38 years (range 17-88). The most commonly observed presenting symptom was acute chest pain (65%). While 47% of the patients were previously healthy, 53% had at least one pre-existing comorbidity, with hypertension being the most prevalent (24%). The European Society of Cardiology diagnostic criteria for the reported AEFIs were fulfilled in twelve cases (71%). The AEFIs occurred after the first vaccine dose in six cases (35%), after the second vaccine dose in ten cases (59%) and after both doses in one case (6%). The median latency of all AEFIs taken together was 14 days (range 1-28) after the first vaccination and 3 days (range 1-17) after the second one. All patients except one were hospitalized (94%) with a median length of stay of 7.5 days (range 3-13). The majority of patients (

Identifiers

PMID34805376
PMCPMC8587334
OpenAlexW3205196874

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.